{"organizations": [], "uuid": "ee5528065533ad35b5cfd6e3a24f2a6100ddded5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/healthNews\r", "section_title": "Reuters: Health News", "url": "https://www.reuters.com/article/us-apotex-ceo/apotex-ceo-desai-resigns-globe-and-mail-idUSKBN1FF2FW", "country": "US", "domain_rank": 408, "title": "Apotex CEO Desai resigns: Globe and Mail", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-26T20:19:00.000+02:00", "replies_count": 0, "uuid": "ee5528065533ad35b5cfd6e3a24f2a6100ddded5"}, "author": "", "url": "https://www.reuters.com/article/us-apotex-ceo/apotex-ceo-desai-resigns-globe-and-mail-idUSKBN1FF2FW", "ord_in_thread": 0, "title": "Apotex CEO Desai resigns: Globe and Mail", "locations": [], "entities": {"persons": [{"name": "desai", "sentiment": "negative"}, {"name": "mail reuters", "sentiment": "negative"}, {"name": "barry sherman", "sentiment": "none"}, {"name": "jack kay", "sentiment": "none"}, {"name": "anil d'silva", "sentiment": "none"}, {"name": "jeremy desai", "sentiment": "none"}, {"name": "john benny", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "apotex", "sentiment": "negative"}, {"name": "globe", "sentiment": "none"}, {"name": "apotex inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Reuters) - Canadian generic drug maker Apotex Inc’s Chief Executive Jeremy Desai has resigned, effective immediately, the company said on Friday.\nDesai resigned to pursue other opportunities, Apotex said in an emailed statement without elaborating.\nCompany veteran Jack Kay will become Apotex’s CEO, a role he has previously held.\nApotex also named Jeff Watson as chief operating officer. Watson served as president of global generics, Apotex’s biggest business.\nReporting by John Benny in Bengaluru; Editing by Anil D'Silva\n ", "external_links": [], "published": "2018-01-26T20:19:00.000+02:00", "crawled": "2018-01-26T21:14:48.014+02:00", "highlightTitle": ""}